AU2009258151A1 - Rasagiline for Parkinson's disease modification - Google Patents

Rasagiline for Parkinson's disease modification Download PDF

Info

Publication number
AU2009258151A1
AU2009258151A1 AU2009258151A AU2009258151A AU2009258151A1 AU 2009258151 A1 AU2009258151 A1 AU 2009258151A1 AU 2009258151 A AU2009258151 A AU 2009258151A AU 2009258151 A AU2009258151 A AU 2009258151A AU 2009258151 A1 AU2009258151 A1 AU 2009258151A1
Authority
AU
Australia
Prior art keywords
rasagiline
patient
parkinson
disease
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2009258151A
Other languages
English (en)
Inventor
Miri Ben-Ami
Eli Eyal
Tamar Goren
Ruth Levy
Sheila Oren
Naim Sayag
Yonatan Weiss
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Original Assignee
Teva Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd filed Critical Teva Pharmaceutical Industries Ltd
Publication of AU2009258151A1 publication Critical patent/AU2009258151A1/en
Priority to AU2016259315A priority Critical patent/AU2016259315A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU2009258151A 2008-06-13 2009-06-12 Rasagiline for Parkinson's disease modification Abandoned AU2009258151A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2016259315A AU2016259315A1 (en) 2008-06-13 2016-11-15 Rasagiline for parkinson's disease modification

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US13193608P 2008-06-13 2008-06-13
US61/131,936 2008-06-13
US18972408P 2008-08-22 2008-08-22
US61/189,724 2008-08-22
PCT/US2009/003528 WO2009151625A1 (en) 2008-06-13 2009-06-12 Rasagiline for parkinson's disease modification

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2016259315A Division AU2016259315A1 (en) 2008-06-13 2016-11-15 Rasagiline for parkinson's disease modification

Publications (1)

Publication Number Publication Date
AU2009258151A1 true AU2009258151A1 (en) 2009-12-17

Family

ID=41415378

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2009258151A Abandoned AU2009258151A1 (en) 2008-06-13 2009-06-12 Rasagiline for Parkinson's disease modification
AU2016259315A Abandoned AU2016259315A1 (en) 2008-06-13 2016-11-15 Rasagiline for parkinson's disease modification

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2016259315A Abandoned AU2016259315A1 (en) 2008-06-13 2016-11-15 Rasagiline for parkinson's disease modification

Country Status (13)

Country Link
US (2) US20090312436A1 (cg-RX-API-DMAC10.html)
EP (2) EP2296462A4 (cg-RX-API-DMAC10.html)
JP (3) JP2011522892A (cg-RX-API-DMAC10.html)
CN (2) CN103893160A (cg-RX-API-DMAC10.html)
AU (2) AU2009258151A1 (cg-RX-API-DMAC10.html)
BR (1) BRPI0909894A2 (cg-RX-API-DMAC10.html)
CA (1) CA2727022A1 (cg-RX-API-DMAC10.html)
EA (1) EA201170018A1 (cg-RX-API-DMAC10.html)
IL (1) IL209131A0 (cg-RX-API-DMAC10.html)
MX (1) MX2010013766A (cg-RX-API-DMAC10.html)
NZ (1) NZ589445A (cg-RX-API-DMAC10.html)
WO (1) WO2009151625A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201008484B (cg-RX-API-DMAC10.html)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060018957A1 (en) * 2004-07-26 2006-01-26 Lerner E I Pharmaceutical dosage forms including rasagiline
ES2371883T3 (es) * 2004-11-24 2012-01-11 Teva Pharmaceutical Industries Ltd. Composiciones de rasagilina de disgregación oral.
US8809310B2 (en) * 2006-02-21 2014-08-19 Teva Pharmaceutical Industries, Ltd. Use of rasagiline for the treatment of multiple system atrophy
AU2007235517B2 (en) 2006-04-03 2013-01-31 Teva Pharmaceutical Industries, Ltd. Use of rasagiline for the treatment of Restless Legs Syndrome
EP1892233A1 (de) 2006-08-18 2008-02-27 Ratiopharm GmbH Neue Salze des Wirkstoffs Rasagilin
EP1987816A1 (de) * 2007-04-30 2008-11-05 Ratiopharm GmbH Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff
US20090062400A1 (en) * 2007-09-05 2009-03-05 Laurence Oron Method of treating glaucoma using rasagiline
US8188149B2 (en) * 2007-09-17 2012-05-29 Teva Pharmaceutical Industries, Ltd. Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss
EA201070842A1 (ru) * 2008-01-11 2011-04-29 Тева Фармасьютикал Индастриз, Лтд. Препаративные формы разагилина, их получение и применение
AU2009258120B2 (en) * 2008-06-10 2014-11-27 Teva Pharmaceutical Industries, Ltd. Rasagiline soft gelatin capsules
JP2011525489A (ja) * 2008-06-19 2011-09-22 テバ ファーマシューティカル インダストリーズ リミティド ラサリジン塩基の精製方法
NZ589547A (en) 2008-06-19 2013-03-28 Teva Pharma Dried rasagiline base having a water content less than 0.5 % by weight
US20100189790A1 (en) * 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline formulation
PT2451771E (pt) 2009-07-09 2014-09-19 Ratiopharm Gmbh Sais de rasagilina e suas preparações farmacêuticas
WO2011087791A1 (en) * 2009-12-22 2011-07-21 Teva Pharmaceutical Industries Ltd. 3-keto-n-propargyl-1-aminoindan
RU2587330C2 (ru) * 2010-07-27 2016-06-20 Тева Фармасьютикал Индастриз Лтд. Применение разагилина для лечения обонятельной дисфункции
WO2012015946A1 (en) * 2010-07-27 2012-02-02 Teva Pharmaceutical Industries Ltd. Dispersion of rasagiline citrate
CN103188933A (zh) * 2010-10-26 2013-07-03 泰华制药工业有限公司 富集氘的雷沙吉兰
CA2732440C (en) * 2011-02-23 2017-10-31 Universite Laval Cystamine analogues for the treatment of parkinson`s disease
CA2851433A1 (en) 2011-10-10 2013-04-18 Teva Pharmaceutical Industries Ltd. R(+)-n-methyl-propargyl-aminoindan
BR112014008555A2 (pt) 2011-10-10 2017-04-18 Teva Pharma r(+)-n-formil-propargil-aminoindano
US20130089611A1 (en) * 2011-10-10 2013-04-11 Teva Pharmaceutical Industries, Ltd. Rasagiline citramide
AR092168A1 (es) 2012-08-17 2015-03-25 Teva Pharma Formulaciones parenterales de rasagilina
CA2943841A1 (en) * 2014-04-01 2015-10-08 Teva Pharmaceutical Industries Ltd. Determination of single nucleotide polymorphisms useful to predict response for rasagiline
EP3432931A1 (en) * 2016-03-26 2019-01-30 Dr. Reddy's Laboratories Ltd. Pharmaceutical compositons for n-propargylamine derivative
EP3606541A1 (en) * 2017-04-05 2020-02-12 Crestovo Holdings LLC Compositions and methods for treating parkinson's disease (pd) and related disorders
CA3127590A1 (en) * 2019-01-28 2020-08-06 Mitochondria Emotion, Inc. Mitofusin activators and methods of use thereof
GB202109826D0 (en) * 2021-07-07 2021-08-18 Bial Portela & Ca Sa Treatment regimens for early idiopathic parkinson's disease

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL92952A (en) * 1990-01-03 1994-06-24 Teva Pharma R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
US5744500A (en) * 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
CN1031995C (zh) * 1991-01-02 1996-06-12 奥韦特有限公司 N-炔丙基-1-氨基茚满的r-对映体的制法
IL99759A (en) * 1991-10-16 1997-06-10 Teva Pharma Mono-fluorinated derivatives of n-propargyl-1-aminoindan, their preparation and pharmaceutical compositions containing them
IL115357A (en) * 1995-09-20 2000-01-31 Teva Pharma Stable compositions containing N-propargyl-1-aminoindan and polyhydric alcohols
IL118836A (en) * 1996-07-11 2001-01-11 Teva Pharma Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan
CA2275425C (en) * 1996-12-18 2009-08-04 Michael Chorev Aminoindan derivatives
AU2002319615A1 (en) * 2001-07-20 2003-03-03 Mount Sinai School Of Medicine Of New York University Methods for diagnosing and treating alzheimer's disease and parkinson's disease
CA2471760A1 (en) * 2001-12-28 2003-07-17 Takeda Chemical Industries, Ltd. Preventives/remedies for urinary disturbance
SI1567152T1 (sl) * 2002-11-15 2013-10-30 Teva Pharmaceutical Industries Ltd. Uporaba rasagilina z riluzolom za zdravljenje amiotrofične lateralne skleroze
US20050031651A1 (en) * 2002-12-24 2005-02-10 Francine Gervais Therapeutic formulations for the treatment of beta-amyloid related diseases
AR044007A1 (es) * 2003-04-11 2005-08-24 Newron Pharmaceuticals Inc Metodos para el tratamiento de la enfermedad de parkinson
US20060018957A1 (en) * 2004-07-26 2006-01-26 Lerner E I Pharmaceutical dosage forms including rasagiline
ES2371883T3 (es) * 2004-11-24 2012-01-11 Teva Pharmaceutical Industries Ltd. Composiciones de rasagilina de disgregación oral.
US7815942B2 (en) * 2005-02-23 2010-10-19 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations of improved content uniformity
US7491847B2 (en) * 2005-11-17 2009-02-17 Teva Pharmaceutical Industries, Ltd. Methods for isolating propargylated aminoindans
US7572834B1 (en) * 2005-12-06 2009-08-11 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations and processes for their preparation
US8809310B2 (en) * 2006-02-21 2014-08-19 Teva Pharmaceutical Industries, Ltd. Use of rasagiline for the treatment of multiple system atrophy
US9066903B2 (en) * 2006-02-28 2015-06-30 The United States Of America As Represented By The Department Of Veterans Affairs Pharmacological treatment of Parkinson's disease
CN101032474B (zh) * 2006-03-06 2011-02-16 重庆医药工业研究院有限责任公司 一种治疗或预防神经系统疾病的雷沙吉兰透皮贴片及其制备方法
AU2007235517B2 (en) * 2006-04-03 2013-01-31 Teva Pharmaceutical Industries, Ltd. Use of rasagiline for the treatment of Restless Legs Syndrome
EP1892233A1 (de) * 2006-08-18 2008-02-27 Ratiopharm GmbH Neue Salze des Wirkstoffs Rasagilin
UA97382C2 (ru) * 2006-12-14 2012-02-10 Тева Фармасьютікл Індастріз, Лтд. Таннат разагилина
AU2007334428B2 (en) * 2006-12-14 2014-05-29 Teva Pharmaceutical Industries, Ltd. Crystalline solid rasagiline base
EP1987816A1 (de) * 2007-04-30 2008-11-05 Ratiopharm GmbH Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff
WO2009032202A1 (en) * 2007-08-29 2009-03-12 Nuon Therapeutics, Inc. Treatment of brain disorders
US20090062400A1 (en) * 2007-09-05 2009-03-05 Laurence Oron Method of treating glaucoma using rasagiline
US8188149B2 (en) * 2007-09-17 2012-05-29 Teva Pharmaceutical Industries, Ltd. Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss
EA201070842A1 (ru) * 2008-01-11 2011-04-29 Тева Фармасьютикал Индастриз, Лтд. Препаративные формы разагилина, их получение и применение
AU2009258120B2 (en) * 2008-06-10 2014-11-27 Teva Pharmaceutical Industries, Ltd. Rasagiline soft gelatin capsules
NZ589547A (en) * 2008-06-19 2013-03-28 Teva Pharma Dried rasagiline base having a water content less than 0.5 % by weight
JP2011525489A (ja) * 2008-06-19 2011-09-22 テバ ファーマシューティカル インダストリーズ リミティド ラサリジン塩基の精製方法
DE102008064061A1 (de) * 2008-12-19 2010-06-24 Ratiopharm Gmbh Feste Zusammensetzung mit dem Wirkstoff Rasagilin
US20100189790A1 (en) * 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline formulation
JP2013507352A (ja) * 2009-10-09 2013-03-04 テバ ファーマシューティカル インダストリーズ リミティド 進行性核上性麻痺の治療のためのラサギリンの使用
WO2011087791A1 (en) * 2009-12-22 2011-07-21 Teva Pharmaceutical Industries Ltd. 3-keto-n-propargyl-1-aminoindan

Also Published As

Publication number Publication date
MX2010013766A (es) 2011-03-15
JP2017081938A (ja) 2017-05-18
NZ589445A (en) 2013-06-28
EA201170018A1 (ru) 2011-08-30
JP2011522892A (ja) 2011-08-04
AU2016259315A1 (en) 2016-12-01
CN103893160A (zh) 2014-07-02
CN102065687A (zh) 2011-05-18
EP2296462A4 (en) 2011-06-15
ZA201008484B (en) 2012-05-30
WO2009151625A1 (en) 2009-12-17
JP2015096532A (ja) 2015-05-21
BRPI0909894A2 (pt) 2015-07-28
EP2666356A1 (en) 2013-11-27
CA2727022A1 (en) 2009-12-17
IL209131A0 (en) 2011-01-31
EP2296462A1 (en) 2011-03-23
US20140243418A1 (en) 2014-08-28
US20090312436A1 (en) 2009-12-17

Similar Documents

Publication Publication Date Title
US20090312436A1 (en) Rasagiline for parkinson's disease modification
Schatzberg et al. A double-blind, placebo-controlled study of venlafaxine and fluoxetine in geriatric outpatients with major depression
Detke et al. Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression
Mintzer et al. Risperidone in the treatment of psychosis of Alzheimer disease: results from a prospective clinical trial
Feighner et al. Multicenter, placebo-controlled, fixed-dose study of citalopram in moderate-to-severe depression
Reimherr et al. A multicenter evaluation of the efficacy and safety of 150 and 300 mg/d sustained-release bupropion tablets versus placebo in depressed outpatients
US20110130466A1 (en) Use of rasagiline for the treatment of progressive supranuclear palsy
Citrome Reprint of: Clinical management of tardive dyskinesia: Five steps to success
TW202304461A (zh) 自發性震顫之治療
TW202142229A (zh) 治療雷葛氏症候群之病患的方法
US20240173280A1 (en) Methods of treating seizure disorders and prader-willi syndrome
KR20180114250A (ko) 아미노피리딘을 사용한 연장 요법을 위한 조성물 및 방법
KR20250034521A (ko) 실조증을 치료하기 위한 릴루졸 전구약물의 용도
US20230270738A1 (en) Methods of treating agitation associated with alzheimer's disease
US20230372335A1 (en) TREATMENT OF COGNITIVE IMPAIRMENT WITH A CNS-PENETRANT sGC STIMULATOR
CN118284412A (zh) 伴中度至重度焦虑和/或社交回避的自闭症谱系障碍受试者易怒症的治疗
WO2024216061A1 (en) Methods of treating depression and anhedonia
WO2024216046A1 (en) Methods of treating anhedonia
HK1192112A (en) Rasagiline for parkinson's disease modification
TW202333705A (zh) 治療與阿茲海默症相關之激越的方法
TW200916091A (en) Neramexane for the treatment of nystagmus
WO2024184180A1 (en) Minzasolmin for use in the treatment of parkinson's disease
WO2024184179A1 (en) Minzasolmin for use in the treatment of parkinson's disease
WO2023214314A1 (en) Vodobatinib for reducing progression of parkinson's disease
WO2024196957A1 (en) Method for treating l-dopa-induced dyskinesia using befiradol

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted